Alnylam Pharmaceuticals holds the cleaner structural position, with profitability as the main driver and growth adding further support. Natera does not offset that deficit through any equally strong structural edge elsewhere. Both sides have seen trend damage — neither carries a clear market edge right now. With both trends damaged, the structural comparison carries most of the weight here.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the Russell 1000 universe, making them directly comparable.
The comparison is mainly decided in profitability, with the rest of the profile carrying less weight. Alnylam Pharmaceuticals, Inc. leads by 18 points on the overall comparison score.
This pair is matched through long-term financial trajectory similarity within the selected peer universe.
This level of similarity signals a strong structural match, even though some dimensions still separate the two companies.
The match is driven mainly by investment intensity and revenue growth trajectory.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
Alnylam Pharmaceuticals, Inc. is stronger, but the price setup still looks more supportive for Natera, Inc..
Valuation position uses peer-relative PE percentile (idx_pct_pe) and peer-relative valuation score where available.
Where ALNY and NTRA each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The profitability lead is mainly driven by a 35-point operating margin advantage.
Alnylam Pharmaceuticals, Inc. also looks less cycle-sensitive, which gives the profile a calmer footing than a pure score split would imply.
Profitability is the clearest driver, and growth also supports Alnylam Pharmaceuticals, Inc.'s broader structural position.
Break down the ALNY vs NTRA comparison across all dimensions with the full interactive tool.
Explore how ALNY and NTRA each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.